Influenza A virus H1N1 vaccines - Vaxxas

Drug Profile

Influenza A virus H1N1 vaccines - Vaxxas

Alternative Names: A/Michigan/45/2015(H1N1)-like-vaccine coated micro-projection array patch; A/Singapore/GP1908/2015 vaccine coated micro-projection array patch

Latest Information Update: 04 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxxas
  • Class Influenza A virus H1N1 vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Influenza A virus H1N1 subtype

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype

Most Recent Events

  • 26 Feb 2018 Phase-I clinical trials in Influenza-A virus H1N1 subtype (Prevention) in Australia (Transdermal) (ACTRN12618000112268)
  • 02 Feb 2018 Vaxxas plans a phase I trial for Influenza-A virus H1N1 subtype infection (Prevention) in Australia in February 2018 (ACTRN12618000112268p)
  • 02 Feb 2018 Influenza A virus H1N1 vaccines - Vaxxas is available for licensing as of 02 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top